Trial · NCT02134717
Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes
NCT02134717, Not applicable, Terminated, Kevin F. Gibson; results first posted 2017-07-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes. Trials, record NCT02134717. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02134717
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes
- NCT number
- NCT02134717
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 3 participants, actual
- Lead sponsor
- Kevin F. Gibson
- Conditions
- Sarcoidosis
- Interventions
- all subjects will receive maraviroc 300mg orally twice a day for 6 weeks, Bronchoscopy with bronchoalveolar lavage, venipunctures, Skin biopsy
- First posted
- 2014-05-09
- Last updated
- 2025-12-03
- Results first posted
- 2017-07-18
- Limitations and caveats
- This study was terminated due to inadequate funding to complete the recruitment and analysis.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Total Cell Count and Differentials in Blood and Bronchoalveolar Lavage Fluid Pre- and Post Maraviroc | 6 weeks | General indicators of inflammation following chemokine receptor 5 (CCR5) inhibition in blood and bronchoalveolar lavage |
| Secondary | Mononuclear Cell (MNC) Activation and T-cell Differentiation | 6 weeks | MNC activation and T-cell differentiation before and after CCR5 inhibition. |
| Secondary | Chemokine Receptor 5 (CCR5) Expression Among These Immune Effector Cells | 6 weeks | CCR5 expression among these immune effector cells before and after CCR5 inhibition. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Total Cell Count and Differentials in Blood and Bronchoalveolar Lavage Fluid Pre- and Post Maraviroc | 6 weeks | Data could not be analyzed | ||
| SECONDARY | Mononuclear Cell (MNC) Activation and T-cell Differentiation | 6 weeks | Study was terminated before data were collected for this outcome measure. | ||
| SECONDARY | Chemokine Receptor 5 (CCR5) Expression Among These Immune Effector Cells | 6 weeks | Study was terminated before data were collected for this outcome measure. |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Total Cell Count and Differentials in Blood and Bronchoalveolar Lavage Fluid Pre- and Post Maraviroc | Group not reported | total cell count and differential in blood and BAL | |||
| Total Cell Count and Differentials in Blood and Bronchoalveolar Lavage Fluid Pre- and Post Maraviroc | Group not reported | Mononuclear cell activation and T cell differentia |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Sarcoidosis Stage II | 3 | |
| Overall Study | COMPLETED | Sarcoidosis Stage II | 3 | |
| Overall Study | NOT COMPLETED | Sarcoidosis Stage II | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Sarcoidosis Stage II | ||
| Total, other adverse events | Sarcoidosis Stage II | 0 | 3 |
| Total, serious adverse events | Sarcoidosis Stage II | 0 | 3 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U01HL112711 | Impact of CCR5 inhibition on Sarcoid Immunophenotypes | KASS, DANIEL J; DUNCAN, STEVEN R | UNIVERSITY OF PITTSBURGH AT PITTSBURGH | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2012 to 2014 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02134717
GET https://conductscience.org/api/trials/v1/NCT02134717/registered